新規コロナウイルス（COVID-19）・疫病に対するAIの世界市場 2020年：企業別・地域別・種類別・用途別市場予測

• 英文タイトル：Global AI to Novel Coronavirus (COVID-19) and Epidemic Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D0804-14682 • 出版社/出版日：GlobalInfoResearch / 2020年7月21日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥487,200 (USD3,480)	▷ お問い合わせ
Multi User	￥730,800 (USD5,220)	▷ お問い合わせ
Corporate User	￥974,400 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、新規コロナウイルス（COVID-19）・疫病に対するAIの世界市場を広く調査・分析し、今後の市場展望をまとめております。新規コロナウイルス（COVID-19）・疫病に対するAIの種類別市場規模（AI追跡、AI予測、AI認識、その他）、用途別市場規模（医療、救急、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Google、Insilico Medicine、BlueDot、Alibaba、SenseTime、Artificial Intelligence in Medical Epidemiology、Iktos、BenevolentAI、Beijing Infervision Technology Co., Ltd.、DEARGEN、SRI Biosciences ・地域別グローバル市場分析 2015年-2020年 ・新規コロナウイルス（COVID-19）・疫病に対するAIの北米市場（アメリカ、カナダ、メキシコ） ・新規コロナウイルス（COVID-19）・疫病に対するAIのヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・新規コロナウイルス（COVID-19）・疫病に対するAIのアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・新規コロナウイルス（COVID-19）・疫病に対するAIの南米市場（ブラジル、アルゼンチン） ・新規コロナウイルス（COVID-19）・疫病に対するAIの中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：AI追跡、AI予測、AI認識、その他 ・用途別分析：医療、救急、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論

Market Overview
The AI to Novel Coronavirus (COVID-19) and Epidemic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The most likely (base case) scenario is that the global AI to Novel Coronavirus (COVID-19) and Epidemic sales will be xx in 2020 from AI to Novel Coronavirus (COVID-19) and Epidemic million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global AI to Novel Coronavirus (COVID-19) and Epidemic market size is expected to grow at xx% or more annually for the next five years.

This report also researches and evaluates the impact of Covid-19 outbreak on the AI to Novel Coronavirus (COVID-19) and Epidemic industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on AI to Novel Coronavirus (COVID-19) and Epidemic and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Market segmentation
AI to Novel Coronavirus (COVID-19) and Epidemic market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, AI to Novel Coronavirus (COVID-19) and Epidemic market has been segmented into:
AI Tracking
AI Predict
AI Recognition
Other

By Application, AI to Novel Coronavirus (COVID-19) and Epidemic has been segmented into:
Medical
Public Emergency
Other

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global AI to Novel Coronavirus (COVID-19) and Epidemic market presented in the report. This section sheds light on the sales growth of different regional and country-level AI to Novel Coronavirus (COVID-19) and Epidemic markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global AI to Novel Coronavirus (COVID-19) and Epidemic market.

The report offers in-depth assessment of the growth and other aspects of the AI to Novel Coronavirus (COVID-19) and Epidemic market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and AI to Novel Coronavirus (COVID-19) and Epidemic Market Share Analysis
AI to Novel Coronavirus (COVID-19) and Epidemic competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, AI to Novel Coronavirus (COVID-19) and Epidemic sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the AI to Novel Coronavirus (COVID-19) and Epidemic sales, revenue and market share for each player covered in this report.

The major players covered in AI to Novel Coronavirus (COVID-19) and Epidemic are:
Google
Insilico Medicine
BlueDot
Alibaba
SenseTime
Artificial Intelligence in Medical Epidemiology
Iktos
BenevolentAI
Beijing Infervision Technology Co., Ltd.
DEARGEN
SRI Biosciences

レポート目次

---

1 AI to Novel Coronavirus (COVID-19) and Epidemic Market Overview
1.1 Product Overview and Scope of AI to Novel Coronavirus (COVID-19) and Epidemic
1.2 Classification of AI to Novel Coronavirus (COVID-19) and Epidemic by Type
1.2.1 Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Type in 2019
1.2.3 AI Tracking
1.2.4 AI Predict
1.2.5 AI Recognition
1.2.6 Other
1.3 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market by Application
1.3.1 Overview: Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Medical
1.3.3 Public Emergency
1.3.4 Other
1.4 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market by Regions
1.4.1 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of AI to Novel Coronavirus (COVID-19) and Epidemic (2015-2025)
1.4.3 North America (USA, Canada and Mexico) AI to Novel Coronavirus (COVID-19) and Epidemic Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) AI to Novel Coronavirus (COVID-19) and Epidemic Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) AI to Novel Coronavirus (COVID-19) and Epidemic Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) AI to Novel Coronavirus (COVID-19) and Epidemic Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) AI to Novel Coronavirus (COVID-19) and Epidemic Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: AI to Novel Coronavirus (COVID-19) and Epidemic Industry Impact
1.5.1 COVID-19 Potential Implications for the AI to Novel Coronavirus (COVID-19) and Epidemic
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on AI to Novel Coronavirus (COVID-19) and Epidemic
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Google
2.1.1 Google Details
2.1.2 Google Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Google SWOT Analysis
2.1.4 Google Product and Services
2.1.5 Google AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, Gross Margin and Market Share (2018-2019)
2.2 Insilico Medicine
2.2.1 Insilico Medicine Details
2.2.2 Insilico Medicine Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Insilico Medicine SWOT Analysis
2.2.4 Insilico Medicine Product and Services
2.2.5 Insilico Medicine AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, Gross Margin and Market Share (2018-2019)
2.3 BlueDot
2.3.1 BlueDot Details
2.3.2 BlueDot Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 BlueDot SWOT Analysis
2.3.4 BlueDot Product and Services
2.3.5 BlueDot AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, Gross Margin and Market Share (2018-2019)
2.4 Alibaba
2.4.1 Alibaba Details
2.4.2 Alibaba Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Alibaba SWOT Analysis
2.4.4 Alibaba Product and Services
2.4.5 Alibaba AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, Gross Margin and Market Share (2018-2019)
2.5 SenseTime
2.5.1 SenseTime Details
2.5.2 SenseTime Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 SenseTime SWOT Analysis
2.5.4 SenseTime Product and Services
2.5.5 SenseTime AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, Gross Margin and Market Share (2018-2019)
2.6 Artificial Intelligence in Medical Epidemiology
2.6.1 Artificial Intelligence in Medical Epidemiology Details
2.6.2 Artificial Intelligence in Medical Epidemiology Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Artificial Intelligence in Medical Epidemiology SWOT Analysis
2.6.4 Artificial Intelligence in Medical Epidemiology Product and Services
2.6.5 Artificial Intelligence in Medical Epidemiology AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, Gross Margin and Market Share (2018-2019)
2.7 Iktos
2.7.1 Iktos Details
2.7.2 Iktos Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Iktos SWOT Analysis
2.7.4 Iktos Product and Services
2.7.5 Iktos AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, Gross Margin and Market Share (2018-2019)
2.8 BenevolentAI
2.8.1 BenevolentAI Details
2.8.2 BenevolentAI Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 BenevolentAI SWOT Analysis
2.8.4 BenevolentAI Product and Services
2.8.5 BenevolentAI AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, Gross Margin and Market Share (2018-2019)
2.9 Beijing Infervision Technology Co., Ltd.
2.9.1 Beijing Infervision Technology Co., Ltd. Details
2.9.2 Beijing Infervision Technology Co., Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Beijing Infervision Technology Co., Ltd. SWOT Analysis
2.9.4 Beijing Infervision Technology Co., Ltd. Product and Services
2.9.5 Beijing Infervision Technology Co., Ltd. AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, Gross Margin and Market Share (2018-2019)
2.10 DEARGEN
2.10.1 DEARGEN Details
2.10.2 DEARGEN Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 DEARGEN SWOT Analysis
2.10.4 DEARGEN Product and Services
2.10.5 DEARGEN AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, Gross Margin and Market Share (2018-2019)
2.11 SRI Biosciences
2.11.1 SRI Biosciences Details
2.11.2 SRI Biosciences Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 SRI Biosciences SWOT Analysis
2.11.4 SRI Biosciences Product and Services
2.11.5 SRI Biosciences AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 AI to Novel Coronavirus (COVID-19) and Epidemic Players Market Share
3.2.2 Top 10 AI to Novel Coronavirus (COVID-19) and Epidemic Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Market Share by Regions
4.2 North America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
4.3 Europe AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
4.5 South America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
5 North America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue by Countries
5.1 North America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue by Countries (2015-2020)
5.2 USA AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
5.3 Canada AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
5.4 Mexico AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
6 Europe AI to Novel Coronavirus (COVID-19) and Epidemic Revenue by Countries
6.1 Europe AI to Novel Coronavirus (COVID-19) and Epidemic Revenue by Countries (2015-2020)
6.2 Germany AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
6.3 UK AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
6.4 France AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
6.5 Russia AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
6.6 Italy AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
7 Asia-Pacific AI to Novel Coronavirus (COVID-19) and Epidemic Revenue by Countries
7.1 Asia-Pacific AI to Novel Coronavirus (COVID-19) and Epidemic Revenue by Countries (2015-2020)
7.2 China AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
7.3 Japan AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
7.4 Korea AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
7.5 India AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
8 South America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue by Countries
8.1 South America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue by Countries (2015-2020)
8.2 Brazil AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
8.3 Argentina AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue AI to Novel Coronavirus (COVID-19) and Epidemic by Countries
9.1 Middle East & Africa AI to Novel Coronavirus (COVID-19) and Epidemic Revenue by Countries (2015-2020)
9.2 Saudi Arabia AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
9.3 UAE AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
9.4 Egypt AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
9.5 South Africa AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Market Share by Type (2015-2020)
10.2 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Forecast by Type (2019-2024)
10.3 AI Tracking Revenue Growth Rate (2015-2025)
10.4 AI Predict Revenue Growth Rate (2015-2025)
10.5 AI Recognition Revenue Growth Rate (2015-2025)
10.6 Other Revenue Growth Rate (2015-2025)
11 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Segment by Application
11.1 Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Application (2015-2020)
11.2 AI to Novel Coronavirus (COVID-19) and Epidemic Market Forecast by Application (2019-2024)
11.3 Medical Revenue Growth (2015-2020)
11.4 Public Emergency Revenue Growth (2015-2020)
11.5 Other Revenue Growth (2015-2020)
12 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Size Forecast (2021-2025)
12.1 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Size Forecast (2021-2025)
12.2 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Forecast by Regions (2021-2025)
12.3 North America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Forecast (2021-2025)
12.4 Europe AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Forecast (2021-2025)
12.6 South America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables
Table 1. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of AI to Novel Coronavirus (COVID-19) and Epidemic by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Google Corporate Information, Location and Competitors
Table 7. Google AI to Novel Coronavirus (COVID-19) and Epidemic Major Business
Table 8. Google AI to Novel Coronavirus (COVID-19) and Epidemic Total Revenue (USD Million) (2017-2018)
Table 9. Google SWOT Analysis
Table 10. Google AI to Novel Coronavirus (COVID-19) and Epidemic Product and Solutions
Table 11. Google AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Insilico Medicine Corporate Information, Location and Competitors
Table 13. Insilico Medicine AI to Novel Coronavirus (COVID-19) and Epidemic Major Business
Table 14. Insilico Medicine AI to Novel Coronavirus (COVID-19) and Epidemic Total Revenue (USD Million) (2018-2019)
Table 15. Insilico Medicine SWOT Analysis
Table 16. Insilico Medicine AI to Novel Coronavirus (COVID-19) and Epidemic Product and Solutions
Table 17. Insilico Medicine AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. BlueDot Corporate Information, Location and Competitors
Table 19. BlueDot AI to Novel Coronavirus (COVID-19) and Epidemic Major Business
Table 20. BlueDot AI to Novel Coronavirus (COVID-19) and Epidemic Total Revenue (USD Million) (2017-2018)
Table 21. BlueDot SWOT Analysis
Table 22. BlueDot AI to Novel Coronavirus (COVID-19) and Epidemic Product and Solutions
Table 23. BlueDot AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Alibaba Corporate Information, Location and Competitors
Table 25. Alibaba AI to Novel Coronavirus (COVID-19) and Epidemic Major Business
Table 26. Alibaba AI to Novel Coronavirus (COVID-19) and Epidemic Total Revenue (USD Million) (2017-2018)
Table 27. Alibaba SWOT Analysis
Table 28. Alibaba AI to Novel Coronavirus (COVID-19) and Epidemic Product and Solutions
Table 29. Alibaba AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. SenseTime Corporate Information, Location and Competitors
Table 31. SenseTime AI to Novel Coronavirus (COVID-19) and Epidemic Major Business
Table 32. SenseTime AI to Novel Coronavirus (COVID-19) and Epidemic Total Revenue (USD Million) (2017-2018)
Table 33. SenseTime SWOT Analysis
Table 34. SenseTime AI to Novel Coronavirus (COVID-19) and Epidemic Product and Solutions
Table 35. SenseTime AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Artificial Intelligence in Medical Epidemiology Corporate Information, Location and Competitors
Table 37. Artificial Intelligence in Medical Epidemiology AI to Novel Coronavirus (COVID-19) and Epidemic Major Business
Table 38. Artificial Intelligence in Medical Epidemiology AI to Novel Coronavirus (COVID-19) and Epidemic Total Revenue (USD Million) (2017-2018)
Table 39. Artificial Intelligence in Medical Epidemiology SWOT Analysis
Table 40. Artificial Intelligence in Medical Epidemiology AI to Novel Coronavirus (COVID-19) and Epidemic Product and Solutions
Table 41. Artificial Intelligence in Medical Epidemiology AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Iktos Corporate Information, Location and Competitors
Table 43. Iktos AI to Novel Coronavirus (COVID-19) and Epidemic Major Business
Table 44. Iktos AI to Novel Coronavirus (COVID-19) and Epidemic Total Revenue (USD Million) (2017-2018)
Table 45. Iktos SWOT Analysis
Table 46. Iktos AI to Novel Coronavirus (COVID-19) and Epidemic Product and Solutions
Table 47. Iktos AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. BenevolentAI Corporate Information, Location and Competitors
Table 49. BenevolentAI AI to Novel Coronavirus (COVID-19) and Epidemic Major Business
Table 50. BenevolentAI AI to Novel Coronavirus (COVID-19) and Epidemic Total Revenue (USD Million) (2017-2018)
Table 51. BenevolentAI SWOT Analysis
Table 52. BenevolentAI AI to Novel Coronavirus (COVID-19) and Epidemic Product and Solutions
Table 53. BenevolentAI AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Beijing Infervision Technology Co., Ltd. Corporate Information, Location and Competitors
Table 55. Beijing Infervision Technology Co., Ltd. AI to Novel Coronavirus (COVID-19) and Epidemic Major Business
Table 56. Beijing Infervision Technology Co., Ltd. AI to Novel Coronavirus (COVID-19) and Epidemic Total Revenue (USD Million) (2017-2018)
Table 57. Beijing Infervision Technology Co., Ltd. SWOT Analysis
Table 58. Beijing Infervision Technology Co., Ltd. AI to Novel Coronavirus (COVID-19) and Epidemic Product and Solutions
Table 59. Beijing Infervision Technology Co., Ltd. AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. DEARGEN Corporate Information, Location and Competitors
Table 61. DEARGEN AI to Novel Coronavirus (COVID-19) and Epidemic Major Business
Table 62. DEARGEN AI to Novel Coronavirus (COVID-19) and Epidemic Total Revenue (USD Million) (2017-2018)
Table 63. DEARGEN SWOT Analysis
Table 64. DEARGEN AI to Novel Coronavirus (COVID-19) and Epidemic Product and Solutions
Table 65. DEARGEN AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. SRI Biosciences Corporate Information, Location and Competitors
Table 67. SRI Biosciences AI to Novel Coronavirus (COVID-19) and Epidemic Major Business
Table 68. SRI Biosciences AI to Novel Coronavirus (COVID-19) and Epidemic Total Revenue (USD Million) (2017-2018)
Table 69. SRI Biosciences SWOT Analysis
Table 70. SRI Biosciences AI to Novel Coronavirus (COVID-19) and Epidemic Product and Solutions
Table 71. SRI Biosciences AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 72. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) by Players (2015-2020)
Table 73. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Share by Players (2015-2020)
Table 74. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) by Regions (2015-2020)
Table 75. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Regions (2015-2020)
Table 76. North America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue by Countries (2015-2020)
Table 77. North America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Countries (2015-2020)
Table 78. Europe AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) by Countries (2015-2020)
Table 79. Asia-Pacific AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) by Countries (2015-2020)
Table 80. South America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue by Countries (2015-2020)
Table 81. South America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Countries (2015-2020)
Table 82. Middle East and Africa AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) by Countries (2015-2020)
Table 83. Middle East and Africa AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Countries (2015-2020)
Table 84. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) by Type (2015-2020)
Table 85. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Share by Type (2015-2020)
Table 86. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Forecast by Type (2021-2025)
Table 87. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue by Application (2015-2020)
Table 88. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Share by Application (2015-2020)
Table 89. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Forecast by Application (2021-2025)
Table 90. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. AI to Novel Coronavirus (COVID-19) and Epidemic Picture
Figure 2. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Type in 2019
Figure 3. AI Tracking Picture
Figure 4. AI Predict Picture
Figure 5. AI Recognition Picture
Figure 6. Other Picture
Figure 7. AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Application in 2019
Figure 8. Medical Picture
Figure 9. Public Emergency Picture
Figure 10. Other Picture
Figure 11. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (USD Million) and Growth Rate (2015-2025)
Figure 12. North America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Europe AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Asia-Pacific AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. South America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Middle East and Africa AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Share by Players in 2019
Figure 19. Global Top 5 Players AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share in 2019
Figure 20. Global Top 10 Players AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share in 2019
Figure 21. Key Players Market Share Trend
Figure 22. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 23. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Regions (2015-2020)
Figure 24. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Regions in 2018
Figure 25. North America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 26. Europe AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 27. Asia-Pacific AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 28. South America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 29. Middle East and Africa AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 30. North America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Countries (2015-2020)
Figure 31. North America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Countries in 2019
Figure 32. USA AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 33. Canada AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 34. Mexico AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 35. Europe AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Countries (2015-2020)
Figure 36. Europe AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Countries in 2019
Figure 37. Germany AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 38. UK AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 39. France AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 40. Russia AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 41. Italy AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 42. Asia-Pacific AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Countries (2015-2020)
Figure 43. Asia-Pacific AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Countries in 2019
Figure 44. China AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 45. Japan AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 46. Korea AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 47. India AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 48. Southeast Asia AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 49. South America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Countries (2015-2020)
Figure 50. South America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Countries in 2019
Figure 51. Brazil AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 52. Argentina AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 53. Middle East and Africa AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Countries (2015-2020)
Figure 54. Middle East and Africa AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Countries in 2019
Figure 55. Saudi Arabia AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 56. UAE AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 57. Egypt AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 58. South Africa AI to Novel Coronavirus (COVID-19) and Epidemic Revenue and Growth Rate (2015-2020)
Figure 59. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Share by Type (2015-2020)
Figure 60. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Share by Type in 2019
Figure 61. Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Share Forecast by Type (2021-2025)
Figure 62. Global AI Tracking Revenue Growth Rate (2015-2020)
Figure 63. Global AI Predict Revenue Growth Rate (2015-2020)
Figure 64. Global AI Recognition Revenue Growth Rate (2015-2020)
Figure 65. Global Other Revenue Growth Rate (2015-2020)
Figure 66. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Share by Application (2015-2020)
Figure 67. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Share by Application in 2019
Figure 68. Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Share Forecast by Application (2021-2025)
Figure 69. Global Medical Revenue Growth Rate (2015-2020)
Figure 70. Global Public Emergency Revenue Growth Rate (2015-2020)
Figure 71. Global Other Revenue Growth Rate (2015-2020)
Figure 72. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 73. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 74. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share Forecast by Regions (2021-2025)
Figure 75. North America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Forecast (2021-2025)
Figure 76. Europe AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Forecast (2021-2025)
Figure 77. Asia-Pacific AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Forecast (2021-2025)
Figure 78. South America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Forecast (2021-2025)
Figure 79. Middle East and Africa AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Forecast (2021-2025)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel

---